Literature DB >> 17122959

Anti-tumor necrosis factor alpha F(ab')2 antibody fragments protect in murine polymicrobial sepsis: concentration and early intervention are fundamental to the outcome.

R Márquez-Velasco1, R Bojalil, A Buelna, F Flores-Guzmán, J Estevez-Ramirez, J Laguna, A M Hernández, A Díaz-Quiñonez, J F Paniagua-Solís.   

Abstract

BACKGROUND: Negative results are frequent using anti-TNFalpha antibodies in sepsis models and clinical trials. METHODS AND
RESULTS: Different prophylactic doses of anti-TNFalpha F(ab')2 antibody fragments were compared for the prevention of death by sepsis induced by cecal ligation and puncture (CLP) in mice. High (10 mg/kg) and very low (0.01 and 0.1 mg/kg) concentrations of anti-TNFalpha antibody fragments were not the most adequate for treating polymicrobial sepsis, since they did not significantly improve survival. To the contrary, intermediate doses (1 mg/kg) significantly protected the challenged animals. Protective activity was also observed when administration of the antibody fragments was initiated early (up to 30 min) after CLP.
CONCLUSIONS: These results suggest that in processes where excessive production of cytokines is involved, the aim should be to return them to their physiologically acting range but not to inhibit their production. The timing of initiating therapy should also be considered in order to maximize the possible benefits.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17122959     DOI: 10.1007/s00011-006-6001-6

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  5 in total

1.  Enhanced survival from CLP-induced sepsis following late administration of low doses of anti-IFNγ F(ab')2 antibody fragments.

Authors:  R Márquez-Velasco; A X Martínez-Velázquez; L M Amezcua-Guerra; F Flores-Guzmán; A Díaz-Quiñonez; F Massó; J Paniagua-Solís; R Bojalil
Journal:  Inflamm Res       Date:  2011-07-02       Impact factor: 4.575

2.  Time profile of oxidative stress and neutrophil activation in ovine acute lung injury and sepsis.

Authors:  Matthias Lange; Csaba Szabo; Daniel L Traber; Eszter Horvath; Atsumori Hamahata; Yoshimitsu Nakano; Lillian D Traber; Robert A Cox; Frank C Schmalstieg; David N Herndon; Perenlei Enkhbaatar
Journal:  Shock       Date:  2012-05       Impact factor: 3.454

3.  Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis.

Authors:  Peter Newham; Daniel Ross; Peter Ceuppens; Shampa Das; James W T Yates; Catherine Betts; Jaimini Reens; Kevin J Randall; Richard Knight; Jennifer S McKay
Journal:  Inflamm Res       Date:  2013-11-17       Impact factor: 4.575

4.  Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock.

Authors:  Rafael Bojalil; María Teresa Mata-González; Fausto Sánchez-Muñoz; Yepci Yee; Iván Argueta; Lucía Bolaños; Luis Manuel Amezcua-Guerra; Tanya Amanda Camacho-Villegas; Edna Sánchez-Castrejón; Walter Jakob García-Ubbelohde; Alexei Fedorovish Licea-Navarro; Ricardo Márquez-Velasco; Jorge Fernando Paniagua-Solís
Journal:  BMC Immunol       Date:  2013-04-02       Impact factor: 3.615

5.  Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis.

Authors:  Andreas von Knethen; Anne Schäfer; Laura Kuchler; Tilo Knape; Urs Christen; Edith Hintermann; Beate Fißlthaler; Katrin Schröder; Ralf P Brandes; Berit Genz; Kerstin Abshagen; Brigitte M Pützer; Lisa K Sha; Andreas Weigert; Shahzad N Syed; Martin Schulz; Ajay M Shah; Andreas Ernst; Mateusz Putyrski; Fabian Finkelmeier; Marina Pesic; Florian Greten; Michael Hogardt; Volkhard A J Kempf; Sandra Gunne; Michael J Parnham; Bernhard Brüne
Journal:  Theranostics       Date:  2019-03-16       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.